Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DDO | Q99489 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105601 | 0.75 | ERN1 (0.48) | ERN1 | |
| SCHEMBL29955769 | 0.75 | CYP1A2 (0.38) | ERN1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL29956734 | 0.75 | ERN1 (0.54) | ERN1KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL29950916 | 0.75 | ERN1 (0.54) | ERN1 | |
| SCHEMBL1619507 | 0.75 | ERN1 (0.54) | ERN1 | |
| SCHEMBL31265477 | 0.75 | ERN1 (0.48) | ERN1ALDH1A1LMNAKMT2ATRIM24 | |
| SCHEMBL29956834 | 0.75 | ERN1 (0.48) | ERN1 | |
| SCHEMBL14115886 | 0.75 | ERN1 (0.48) | ERN1ALDH1A1LMNAKMT2ATRIM24 | |
| SCHEMBL21232612 | 0.72 | ESR2 (0.42) | ERN1KDM4EKMT2A | |
| SCHEMBL29956411 | 0.71 | ALOX5AP (0.34) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928233-B2 | Spiroindolinone pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100204257-A1 | SPIROINDOLINONE PYRIDINE DERIVATIVES | CHEN LI | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204257-A1 | SPIROINDOLINONE PYRIDINE DERIVATIVES | RB1, KRAS, WEE1 | ERN1 1347/4885KDM4E 1739/4885MEN1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.